RecruitingPhase 2NCT07456488
The Effect of 0.01% Atropine Eye Drops on Axial Length and Refraction in Myopic Children Compared to a Control Group
Sponsor
Liaquat National Hospital & Medical College
Enrollment
60 participants
Start Date
Jul 13, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
In this study, atropine 0.01% eye drops will be given to myopic children once at night daily for 6 months as compared to a control group to see the effect on axial length and refraction
Eligibility
Min Age: 4 YearsMax Age: 16 Years
Inclusion Criteria7
- Children aged 4-16 years
- Both genders
- Myopia of baseline SER of -1.00D or more
- Astigmatism less than or equal to -2.50D
- No medical history predisposing severe myopia (e.g., Marfan syndrome, Stickler syndrome, and retinopathy of prematurity), abnormal ocular refractive anatomy (e.g., keratoconus, lenticonus, and spherophakia)
- No history of other vision-threatening ocular diseases or previous intraocular surgery.
- No current or previous use of atropine or pirenzipine, contact lenses or other forms of treatment that may affect myopia progression.
Exclusion Criteria8
- Astigmatism ≥ 2.5 D
- Anisometropia\>1 D
- Best corrected visual acuity \< 0.5 (6/12)
- Prior intraocular surgery
- Allergy to atropine eye drops
- Systemic diseases associated with myopia such as Marfan syndrome, Stickler syndrome
- History of cardiac or significant respiratory diseases
- Lack of consent for participating in the study
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGAtropine 0.01% eye drops
Eye drops atropine 0.01% given once nightly to group A for 6 months
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07456488